API | live tetravalent chimeric dengue vaccine

live tetravalent chimeric dengue vaccine (DENGVAXIA) Report issue

Vaccine Approved ^FDA

AACT

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

chimeric tetravalent dengue vaccine (serotype 1, 2, 3, 4) | cyd dengue vaccine | live tetravalent chimeric dengue vaccine | tetravalent blending vdv-2/cyd-1,3,4 dengue (vero) | tetravalent chimeric dengue vaccine | tetravalent cyd-1,2,3,4 dengue (vero) | tetravalent dengue vaccine (tvdv) with vaxfectin | tetravalent dengue vaccine tvdv with vaxfectin

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Dengue (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Dengue (Phase 3)

Dengue Virus (Phase 2)

Healthy Volunteers (Phase 3)

HIV (Phase 2)

Papillomavirus Infections (Phase 3)

Severe Dengue (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 20
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue